Drug Trial Radar · NCT03150810
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
139
Actual
Start
Jun 28, 2017
Primary completion
May 4, 2023
Study completion May 4, 2023
Sponsor
- Lead sponsor
- BeiGeneBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- Collaborators
- Myriad Genetics, Inc.
- First posted
- May 12, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study was to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.
Conditions
- Locally Advanced or Metastatic Solid Tumors
Interventions
PamiparibDrug
Administered by mouth as a capsule twice daily
TemozolomideDrug
TMZ at various doses administered by mouth as a capsule once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: From first dose of study drug(s) to 28 days post-dose (up to approximately 1 year and 6 months)
- Number of Participants Experiencing Adverse Events (AEs)Time frame: From the first dose of study drug(s) to 30 days after the last dose; up to approximately 5 years and 10 months
- Objective Response Rate (ORR)Time frame: Up to approximately 5 years and 10 months
Locations
22 sites in 4 countries. Site status is shown where the registry gives one.
Start Midwest
Grand Rapids, Michigan
Washington University in St Louis
St Louis, Missouri
Mount Sinai Prime
New York, New York
Montefiore Medical Park At Eastchester Einstein Campus
The Bronx, New York
Sarah Cannon Cancer Center
Nashville, Tennessee
Texas Oncology (Loop) Usor
Dallas, Texas
The University of Texas Md Anderson Cancer Center
Houston, Texas
Chris Obrien Lifehouse
Camperdown, New South Wales, Australia
Saint Vincents Hospital Sydney
Darlinghurst, New South Wales, Australia
Icon Cancer Centre South Brisbane
South Brisbane, Queensland, Australia
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia
Hospital Universitario Vall Dhebron
Barcelona, Spain
Ico H Duran I Reynals
Barcelona, Spain
Hospital Universitario Ramon Y Cajal
Madrid, Spain
Start Madrid Fundacion Jimenez Diaz
Madrid, Spain
Centro Integral Oncologico Clara Campal
Madrid, Spain
Hospital Universitario Virgen de La Macarena
Seville, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom
Northern Centre For Cancer Care
High Heaton, United Kingdom
University College Hospital
London, United Kingdom
Sarah Cannon Research Institute Uk
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.